Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

  title={Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma},
  author={Georgina V. Long and Axel Hauschild and Mario Santinami and Victoria G. Atkinson and Mario Mandal{\`a} and Vanna Chiarion-Sileni and James Larkin and Marta Nyakas and Caroline Dutriaux and Andrew Haydon and Caroline Robert and Laurent Mortier and Jacob Schachter and Dirk Schadendorf and Thierry Lesimple and Ruth Plummer and Ran Ji and Pingkuan Zhang and Bijoyesh Mookerjee and Jeffrey J. Legos and Richard F. Kefford and Reinhard Dummer and John M. Kirkwood},
  journal={The New England Journal of Medicine},
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. METHODS In this double‐blind, placebo‐controlled, phase 3 trial, we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF… 

Figures and Tables from this paper

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.

The Clinical Efficacy of Dabrafenib Plus Trametinib Combination Treatment in Stage III/IVBRAF-Mutated Melanoma

  • L. Rui
  • Biology, Medicine
    Biomedical Journal of Scientific & Technical Research
  • 2018
These clinical trials identify combination treatment of dabrafenib plus trametinib as front-line therapy in stage III/IV BRAF-mutated melanoma.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

As adjuvant therapy for high‐risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence‐free survival than placebo, with no new toxic effects identified.

Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

While first‐line efficacy appears comparable to trial populations, BRAF‐mutant patients failing prior BRAF/MEK inhibitors show less response, particularly in the setting of serine/threonine‐protein kinase B‐Raf‐targeted therapy.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

  • A. HauschildR. Dummer G. Long
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
An updated RFS analysis on the basis of extended study follow-up and a cure-rate model analysis suggested that dabrafenib plus trametinib benefited patients regardless of baseline factors, including disease stage, nodal metastatic burden, and ulceration.

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma

Adjuvant treatment of melanoma with combination D+T is associated with treatment-limiting toxicities in the majority of this patient group, and patients should be carefully monitored throughout therapy.



Improved overall survival in melanoma with combined dabrafenib and trametinib.

Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

  • G. LongJ. Weber K. Flaherty
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor-naive patients with BRAF V600 mutation-positive metastatic melanoma, and approximately 20% were progression free at 3 years.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  • G. LongK. Flaherty J. Grob
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
It is demonstrated that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.

Targeted agents and immunotherapies: optimizing outcomes in melanoma

The clinical trial data that established the standard-of-care treatment approaches for advanced-stage melanoma are reviewed and a rational approach to frontline-treatment selection for each individual patient with BRAF-mutant melanoma is outlined.